Compare LECO & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LECO | VTRS |
|---|---|---|
| Founded | 1895 | 1961 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 12.0B |
| IPO Year | N/A | N/A |
| Metric | LECO | VTRS |
|---|---|---|
| Price | $241.93 | $11.69 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 6 |
| Target Price | ★ $242.56 | $11.50 |
| AVG Volume (30 Days) | 369.7K | ★ 7.4M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | 1.30% | ★ 4.19% |
| EPS Growth | ★ 11.30 | N/A |
| EPS | ★ 9.34 | N/A |
| Revenue | $4,176,319,000.00 | ★ $14,124,400,000.00 |
| Revenue This Year | $7.92 | N/A |
| Revenue Next Year | $6.01 | $1.16 |
| P/E Ratio | $26.08 | ★ N/A |
| Revenue Growth | ★ 3.24 | N/A |
| 52 Week Low | $161.11 | $6.85 |
| 52 Week High | $252.00 | $12.78 |
| Indicator | LECO | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 55.37 | 69.15 |
| Support Level | $240.17 | $10.67 |
| Resistance Level | $252.00 | $11.83 |
| Average True Range (ATR) | 5.72 | 0.26 |
| MACD | 0.35 | 0.07 |
| Stochastic Oscillator | 50.59 | 88.31 |
Lincoln Electric is a leading manufacturer of welding, cutting, and brazing products. Its portfolio includes arc-welding solutions, plasma and oxy-fuel cutting systems, brazing and soldering alloys, and automation solutions. Lincoln Electric serves clients across general fabrication, heavy industries, automotive, construction, shipbuilding, energy, and process industries, among others. Based in Cleveland, Lincoln Electric operates in 19 countries and employs 11,000 worldwide. The company generated roughly $4 billion in sales in 2024.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.